



衛生福利部國民健康署 函

地址：103205 臺北市大同區塔城街
36號

聯絡人：賴玫均

聯絡電話：02-25220888 分機：760

傳真：02-25220774

電子郵件：meichun123@hpa.gov.tw

受文者：國立臺灣大學(癌症登記中心)

發文日期：中華民國114年12月29日

發文字號：國健癌字第1140361519號

速別：普通件

密等及解密條件或保密期限：

附件：版本差異說明1份

主旨：有關美國癌症聯合委員會（AJCC）癌症分期手冊第9版（Version 9）最新出版之口咽癌與唾液腺癌更新內容，請依說明段辦理，請查照。

說明：

- 一、最新美國癌症聯合委員會（下稱AJCC）癌症分期手冊第9版（Version 9）於114年11月出版人類乳突病毒（HPV）相關之口咽癌與唾液腺癌之癌症分期系統，適用於115年1月1日起新診斷之個案，相關TNM與期別編碼對應表，與比對前後版本差異處，請見附件。有關AJCC書籍資訊請參考下列網址：<https://reurl.cc/jmaW5D>。
- 二、自115年起，所有癌症個案申報全面採用114年12月修訂之「114年V.1台灣癌症登記長表/短表摘錄手冊、癌症部位特定因子編碼手冊」規則申報。因前述手冊之附錄B：特定部位編碼指引及手術編碼進行些微更新（更新部分如綠色網底），請逕至台灣癌症登記中心網站下載前述手冊，網址：https://twcr.tw/?page_id=1809。
- 三、為提升國家癌症登記年報完成時效，俾利提前本署國家癌症登記年報記者會公告時程，將於115年2月底開始進

國立臺灣
公文系統騎

行「113診斷年院際複查」作業，相關內容另行通知，請貴院協助優先回復複查作業。

四、另，114年度需完成5年追蹤之個案為109（含）年前診斷之個案，請務必於115年2月28日前完成癌症個案5年追蹤資料申報，以免影響當年度之經費核銷計算與115年追蹤率成績。

五、如有任何疑問，請逕洽癌症登記中心，聯絡電話：（02）2351-2024。

正本：國立臺灣大學醫學院附設醫院、臺北榮民總醫院、三軍總醫院附設民眾診療服務處、臺北市立聯合醫院中興院區、臺北市立聯合醫院仁愛院區、臺北市立聯合醫院和平院區、國立臺灣大學醫學院附設醫院北護分院、基督復臨安息日會醫療財團法人臺安醫院、台灣基督長老教會馬偕醫療財團法人馬偕紀念醫院、臺北醫學大學附設醫院、長庚醫療財團法人林口長庚紀念醫院、國泰醫療財團法人國泰綜合醫院、宏恩醫療財團法人宏恩綜合醫院、中山醫療社團法人中山醫院、三軍總醫院松山分院附設民眾診療服務處、中心診所醫療財團法人中心綜合醫院、博仁綜合醫院、臺北市立聯合醫院婦幼院區、臺北市立聯合醫院陽明院區、西園醫療社團法人西園醫院、景美醫院、臺北市立聯合醫院忠孝院區、醫療財團法人辜公亮基金會和信治癌中心醫院、新光醫療財團法人新光吳火獅紀念醫院、振興醫療財團法人振興醫院、臺北市立萬芳醫院—委託臺北醫學大學辦理、衛生福利部胸腔病院、康寧醫療財團法人康寧醫院、臺北市立關渡醫院—委託臺北榮民總醫院經營、中國醫藥大學附設醫院臺北分院、國立臺灣大學醫學院附設醫院癌醫中心分院、衛生福利部基隆醫院、醫療財團法人台灣區煤礦業基金會台灣礦工醫院、三軍總醫院附設基隆民眾診療服務處、長庚醫療財團法人基隆長庚紀念醫院、衛生福利部臺北醫院、天主教耕莘醫療財團法人耕莘醫院、板橋中興醫院、新北市立聯合醫院、醫療財團法人徐元智先生醫藥基金會亞東紀念醫院、天主教耕莘醫療財團法人永和耕莘醫院、宏仁醫院、行天宮醫療志業醫療財團法人恩主公醫院、同仁醫院、新泰綜合醫院、仁愛醫院、佛教慈濟醫療財團法人台北慈濟醫院、國泰醫療財團法人汐止國泰綜合醫院、衛生福利部雙和醫院(委託臺北醫學大學興建經營)、輔仁大學學校財團法人輔仁大學附設醫院、新北市立土城醫院(委託長庚醫療財團法人興建經營)、國立陽明交通大學附設醫院、醫療財團法人羅許基金會羅東博愛醫院、天主教靈醫會醫療財團法人羅東聖母醫院、臺北榮民總醫院蘇澳分院、宜蘭仁愛醫療財團法人宜蘭仁愛醫院、臺北榮民總醫院員山分院、國立臺灣大學醫學院附設醫院新竹臺大分院新竹醫院、臺北榮民總醫院新竹分院、南門綜合醫院、國軍新竹地區醫院附設民眾診療服務處、東元醫療社團法人東元綜合醫院、天主教仁慈醫療財團法人仁慈醫院、大安醫院、新仁醫院、台灣基督長老教會馬偕醫療財團法人新竹馬偕紀念醫院、國泰醫療財團法人新竹國泰綜合醫院、中

國醫藥大學新竹附設醫院、國立臺灣大學醫學院附設醫院新竹臺大分院生醫醫院、沙爾德聖保祿修女會醫療財團法人聖保祿醫院、衛生福利部桃園醫院、國軍桃園總醫院附設民眾診療服務處、敏盛綜合醫院、陽明醫院(桃園)、龍潭敏盛醫院、聯新國際醫院桃新分院、天成醫院、臺北榮民總醫院桃園分院、聯新國際醫院、怡仁綜合醫院、天成醫療社團法人天晟醫院、衛生福利部桃園醫院新屋分院、重光醫院、衛生福利部苗栗醫院、李綜合醫療社團法人苑裡李綜合醫院、為恭醫療財團法人為恭紀念醫院、大千綜合醫院、協和醫院、梓榮醫療社團法人弘大醫院、衛生福利部臺中醫院、中山醫學大學附設醫院、國軍臺中總醫院附設民眾診療服務處、澄清綜合醫院、國軍臺中總醫院附設民眾診療服務處中清分院、臺中榮民總醫院、中國醫藥大學附設醫院、仁愛醫療財團法人台中仁愛醫院、仁愛醫療財團法人大里仁愛醫院、澄清綜合醫院中港分院、林新醫療社團法人林新醫院、中國醫藥大學附設醫院台中東區分院、光田醫療社團法人光田綜合醫院、童綜合醫療社團法人童綜合醫院、衛生福利部豐原醫院、李綜合醫療社團法人大甲李綜合醫院、清泉醫院、賢德醫院、中國醫藥大學附設醫院豐原分院、佛教慈濟醫療財團法人台中慈濟醫院、亞洲大學附屬醫院、林新醫療社團法人烏日林新醫院、衛生福利部彰化醫院、彰化基督教醫療財團法人彰化基督教醫院、秀傳醫療社團法人秀傳紀念醫院、彰化基督教醫療財團法人二林基督教醫院、員榮醫療社團法人員榮醫院、彰化基督教醫療財團法人漢銘基督教醫院、員林何醫院、惠來醫療社團法人宏仁醫院、秀傳醫療財團法人彰濱秀傳紀念醫院、彰化基督教醫療財團法人鹿港基督教醫院、彰化基督教醫療財團法人員林基督教醫院、衛生福利部南投醫院、埔基醫療財團法人埔里基督教醫院、臺中榮民總醫院埔里分院、佑民醫療社團法人佑民醫院、竹山秀傳醫療社團法人竹山秀傳醫院、彰化基督教醫療財團法人南投基督教醫院、衛生福利部嘉義醫院、天主教中華聖母修女會醫療財團法人天主教聖馬爾定醫院、臺中榮民總醫院嘉義分院、衛生福利部朴子醫院、戴德森醫療財團法人嘉義基督教醫院、臺中榮民總醫院灣橋分院、佛教慈濟醫療財團法人大林慈濟醫院、長庚醫療財團法人嘉義長庚紀念醫院、陽明醫院、天主教若瑟醫療財團法人若瑟醫院、國立臺灣大學醫學院附設醫院雲林分院、諸元內科醫院、中國醫藥大學北港附設醫院、國立成功大學醫學院附設醫院斗六分院、彰化基督教醫療財團法人雲林基督教醫院、長庚醫療財團法人雲林長庚紀念醫院、衛生福利部臺南醫院、奇美醫療財團法人奇美醫院、郭綜合醫院、國立成功大學醫學院附設醫院、台南市立醫院(委託秀傳醫療社團法人經營)、台灣基督長老教會新樓醫療財團法人台南新樓醫院、臺南市立安南醫院一委託中國醫藥大學興建經營、衛生福利部新營醫院、高雄榮民總醫院臺南分院、奇美醫療財團法人佳里奇美醫院、台灣基督長老教會新樓醫療財團法人麻豆新樓醫院、衛生福利部臺南醫院新化分院、奇美醫療財團法人柳營奇美醫院、高雄市立民生醫院、財團法人私立高雄醫學大學附設中和紀念醫院、國軍高雄總醫院附設民眾診療服務處、阮綜合醫療社團法人阮綜合醫院、天主教聖功醫療財團法人聖功醫院、國軍左營總醫院附設民眾診療服務處、高雄市立聯合醫院、高雄榮民總醫院、祐生醫院、信義醫療財團法人高雄基督教醫院、安泰醫院、健仁醫院、健新醫院、高雄市立小港醫院(委託財團法人私立高雄醫學大學經營)、高雄市立

國立臺灣
公文系統

大學
印章

大同醫院、義大醫療財團法人義大大昌醫院、謝外科醫院、衛生福利部旗山醫院、高雄市立鳳山醫院（委託長庚醫療財團法人經營）、國軍高雄總醫院岡山分院附設民眾診療服務處、長庚醫療財團法人高雄長庚紀念醫院、高雄市立岡山醫院（委託秀傳醫療社團法人經營）、建佑醫院、光雄長安醫院、高新醫院、文雄醫院、義大醫療財團法人義大醫院、義大醫療財團法人義大癌治療醫院、財團法人私立高雄醫學大學附設高醫岡山醫院、衛生福利部澎湖醫院、三軍總醫院澎湖分院附設民眾診療服務處、衛生福利部屏東醫院、輔英科技大學附設醫院、屏基醫療財團法人屏東基督教醫院、國軍高雄總醫院附設屏東民眾診療服務處、民眾醫院、南門醫療社團法人南門醫院、屏東榮民總醫院龍泉分院、安泰醫療社團法人安泰醫院、寶建醫療社團法人寶建醫院、枋寮醫療社團法人枋寮醫院、屏東榮民總醫院、衛生福利部臺東醫院、東基醫療財團法人台東基督教醫院、台灣基督長老教會馬偕醫療財團法人台東馬偕紀念醫院、臺北榮民總醫院臺東分院、衛生福利部花蓮醫院、臺北榮民總醫院玉里分院、臺灣基督教門諾會醫療財團法人門諾醫院、國軍花蓮總醫院附設民眾診療服務處、佛教慈濟醫療財團法人花蓮慈濟醫院、臺北榮民總醫院鳳林分院、衛生福利部金門醫院

副本：國立臺灣大學(癌症登記中心)

114/12/29
12:01:27

臺灣大學
騎縫章

Oropharynx (HPV-Associated)

Cancers Staged Using This Staging System

Human papillomavirus (HPV) associated oropharyngeal squamous cell carcinoma (HPV+ OPSCC) is staged using this system.

Cancers NOT Staged Using This Staging System

<i>These histopathologic types of cancer...</i>	<i>Are staged according to the classification for...</i>
<i>HPV-independent carcinomas of the oropharynx</i>	<i>Oropharynx (HPV-independent) and hypopharynx</i>
<i>Neuroendocrine carcinomas of the oropharynx</i>	<i>Oropharynx (HPV-independent) and hypopharynx</i>
<i>Mucosal melanomas</i>	<i>Mucosal melanoma of the head and neck</i>
<i>Salivary gland carcinomas</i>	<i>Salivary glands</i>

Identification of Primary Site

C01.9 Base of tongue, NOS

C02.4 Lingual tonsil

C05.1 Soft palate, NOS

C05.2 Uvula

C09.0 Tonsillar fossa

C09.1 Tonsillar pillar

C09.8 Overlapping lesion of tonsil

C09.9 Tonsil, NOS

C10.0 Vallecula

C10.1 Anterior surface of epiglottis

C10.2 Lateral wall of oropharynx

C10.3 Posterior pharyngeal wall

C10.8 Overlapping lesion of oropharynx

C10.9 Oropharynx, NOS

Histopathologic Type

Code	Description
8085	Squamous cell carcinoma, HPV-associated
8072	Non-keratinizing squamous cell carcinoma
8071	Keratinizing squamous cell carcinoma
8052	Papillary squamous cell carcinoma
8560	Adenosquamous carcinoma
8560	Ciliated adenosquamous carcinoma
8082	Lymphoepithelial carcinoma
8074	Spindle cell/sarcomatoid squamous cell carcinoma
8083	Basaloid squamous cell carcinoma

Sources: WHO Classification of Tumours Editorial Board. *Head and neck tumours*. Lyon (France): International Agency for Research on Cancer, 2023. (WHO Classification of Tumours series, 5thed.; vol. 9).

International Agency for Research on Cancer, World Health Organization. International Classification of Diseases for Oncology. ICD-O-3.2 Online. Used with permission.

Definition of Primary Tumor (T)

T Category	T Criteria
T0	No evidence of primary tumor
T1	Tumor ≤ 2 cm in greatest dimension
T2	Tumor > 2 cm but ≤ 4 cm in greatest dimension
T3	Tumor > 4 cm in greatest dimension or extension to lingual surface of epiglottis
T4	Tumor invades any of the following: <ul style="list-style-type: none"> • Larynx* • Deep/extrinsic muscle of the tongue (genioglossus, hyoglossus, palatoglossus, and styloglossus) • Pterygoid muscles (medial and/or lateral) • Hard palate • Mandible • Pterygoid plates (medial and/or lateral) • Nasopharynx • Skull base • Encases carotid artery

*Mucosal extension to lingual surface of epiglottis from primary tumors of the base of the tongue and vallecula does not constitute invasion of the larynx.

Primary Tumor Suffix

(m) Multiple synchronous primary tumors

Definition of Regional Lymph Nodes (N) Clinical N (cN)

N Category	N Criteria
NX	Regional lymph nodes cannot be assessed
N0	No tumor involvement of regional lymph node(s)
N1	Tumor involvement of ipsilateral (同側) lymph node(s), all ≤ 6 cm in greatest dimension, without unequivocal imaging-detected and/or clinical extranodal extension
N2	Tumor involvement of ipsilateral lymph node(s), all ≤ 6 cm in greatest dimension, with unequivocal imaging-detected and/or clinical extranodal extension OR Tumor involvement of contralateral (對側) or bilateral (雙側) lymph node(s), all ≤ 6 cm in greatest dimension without unequivocal imaging-detected and/or clinical extranodal extension
N3	Tumor involvement of lymph node(s) > 6 cm in greatest dimension OR Tumor involvement of contralateral or bilateral lymph node(s) with unequivocal imaging-detected and/or clinical extranodal extension

Definition of Regional Lymph Nodes (N) Pathological N (pN)

N Category	N Criteria
NX	Regional lymph nodes cannot be assessed
N0	No tumor involvement of regional lymph node(s)
N1	Tumor involvement of 1-4 lymph nodes without definitive pathological extranodal extension
N1a	Tumor involvement of 1 lymph node without definitive pathological extranodal extension
N1b	Tumor involvement of 2-4 lymph nodes without definitive pathological extranodal extension
N2	Tumor involvement of 1-4 lymph nodes with definitive pathological extranodal extension OR Tumor involvement of > 4 lymph nodes without definitive pathological extranodal extension
N3	Tumor involvement of > 4 lymph nodes with definitive pathological extranodal extension

Regional Lymph Nodes Suffix

(sn) Sentinel node procedure

(f) FNA or core needle biopsy

Definition of Distant Metastasis (M)

M Category	M Criteria
cM0	No distant metastasis
cM1	Distant metastasis
pM1	Microscopic confirmation of distant metastasis

AJCC Prognostic Stage Groups

Clinical Stage Group Table

When T is...	And N is...	And M is...	Then the stage group is...
T0	N1	M0	I
T1-T2	N0-N1	M0	I
T0-T2	N2	M0	II
T3	N0-N2	M0	II
T0-T3	N3	M0	III
T4	Any N	M0	III
Any T	Any N	M1	IV

Pathological Stage Group Table

When T is...	And N is...	And M is...	Then the stage group is...
T0	N1	M0	I
T1-T2	N0-N1	M0	I
T0-T2	N2-N3	M0	II
T3	N0-N2	M0	II
T3	N3	M0	III
T4	Any N	M0	III
Any T	Any N	M1	IV

Clinical Stage Group					Pathological Stage Group				
	N0	N1	N2	N3		N0	N1	N2	N3
T0	-	I	II	III	T0	-	I	II	II
T1	I	I	II	III	T1	I	I	II	II
T2	I	I	II	III	T2	I	I	II	II
T3	II	II	II	III	T3	II	II	II	III
T4	III	III	III	III	T4	III	III	III	III
M1	IV	IV	IV	IV	M1	IV	IV	IV	IV

References :

<https://www.facs.org/quality-programs/cancer-programs/american-joint-committee-on-cancer/version-9/>

https://www.amazon.com/gp/product/B0G2TCQQB?ref=dbs_m_mng_rwt_calw_tkin_16&storeType=ebooks&qid=1763560154&sr=8-13

Salivary Glands

Cancers Staged Using This Staging System

All malignancies arising in the major and minor salivary glands are staged using this system.

Cancers NOT Staged Using This Staging System

<i>These histopathologic types of cancer...</i>	<i>Are staged according to the classification for...</i>
<i>Cutaneous squamous cell carcinomas</i>	<i>Cutaneous carcinoma of the head and neck</i>
<i>Mucosal squamous cell carcinomas</i>	<i>Specific head and neck primary site</i>
<i>Neuroendocrine carcinomas</i>	<i>Specific head and neck primary site</i>
<i>Lymphomas</i>	<i>Hodgkin and non-Hodgkin lymphoma</i>
<i>Sarcomas</i>	<i>Soft tissue sarcoma of the head and neck</i>
<i>Mucosal melanomas</i>	<i>Mucosal melanoma of the head and neck</i>

Identification of Primary Site

Major Salivary Glands

C07.9 Parotid gland

C08.0 Submandibular gland

C08.1 Sublingual gland

C08.8 Overlapping lesion of major salivary glands

C08.9 Major salivary gland, NOS

Minor Salivary Glands

C00.3 Mucosa of upper lip

C00.4 Mucosa of lower lip

C00.5 Mucosa of lip, NOS

C01 Base of tongue

C02 Other and unspecified parts of tongue

C03 Gum

C04 Floor of mouth

C05 Palate

C06 Other and unspecified parts of mouth

C09 Tonsil

C10 Oropharynx

C11 Nasopharynx

C12 Pyriform sinus

C13 Hypopharynx

*C14 Other and ill-defined sites in lip, oral cavity
and pharynx*

C15.0 Cervical esophagus

C15.3 Upper third of esophagus

C30 Nasal cavity and middle ear

C31 Accessory sinuses

C32 Larynx

C33 Trachea

C41.1 Mandible

Histopathologic Type

Code	Description
8010	Carcinoma, NOS
8082	Lymphoepithelial carcinoma
8140	Adenocarcinoma, NOS
8147	Basal cell adenocarcinoma
8200	Adenoid cystic carcinoma
8310	Hyalinizing clear cell carcinoma
8407	Sclerosing microcystic adenocarcinoma
8410	Sebaceous carcinoma
8430	Mucoepidermoid carcinoma
8480	Mucinous adenocarcinoma
8500	Salivary duct carcinoma
8500	Intraductal carcinoma
8502	Secretory carcinoma
8502	Microsecretory adenocarcinoma
8525	Polymorphous adenocarcinoma
8550	Acinic cell carcinoma
8562	Epithelial-myoepithelial carcinoma
8980	Carcinosarcoma
8982	Myoepithelial carcinoma
8000*	<i>Neoplasm, malignant</i>

* Histology is not ideal for clinical use in patient care, as it describes an unspecified or outdated diagnosis. Data collectors may use this code only if there is not enough information in the medical record to document a more specific diagnosis.

Sources: WHO Classification of Tumours Editorial Board. Head and neck tumours. Lyon (France): International Agency for Research on Cancer, 2023. (WHO classification of tumours series, 5th ed.; vol. 9).

Definition of Primary Tumor (T)

T Category	T Criteria
TX	Primary tumor cannot be assessed
T0	No evidence of primary tumor
Tis	Carcinoma <i>in situ</i>
T1	Tumor ≤ 2 cm in greatest dimension without extraparenchymal extension*
T2	Tumor > 2 cm but ≤ 4 cm in greatest dimension without extraparenchymal extension*
T3	<ul style="list-style-type: none"> • Tumor > 4 cm in greatest dimension and/or • Gross extraparenchymal extension (for major salivary glands)*
T4	Tumor invades immediately and/or beyond adjacent structures
T4a	Tumor invades any immediately adjacent structures including: <ul style="list-style-type: none"> • Skin • Bone** • Cartilage • Solid organ parenchyma • Esophagus • Trachea • Named nerve
T4b	Tumor invades beyond any adjacent structures including: <ul style="list-style-type: none"> • Encasement of carotid artery • Base of skull invasion (except nasopharynx) • Spinal column invasion • Intracranial invasion • Orbital apex • Prevertebral space • Mediastinal structures • Masticator space

*Extraparenchymal extension is clinical or macroscopic evidence of invasion of soft tissues or nerve, except those listed under T4a and T4b. Microscopic evidence alone does not constitute extraparenchymal extension for classification purposes.

**The following scenarios are not considered T category defining "bone invasion":

1) Destruction of intrinsic sinus bone in sinonasal primaries; 2) Erosion of cortical bone; 3) Primary intraosseous (central) salivary gland tumors.

Primary Tumor Suffix

(m) Multiple synchronous primary tumors

Definition of Regional Lymph Nodes (N) Clinical N (cN)

N Category	N Criteria
NX	Regional lymph nodes cannot be assessed
N0	No tumor involvement of regional lymph node(s)
N1	Tumor involvement of 1-3 lymph node(s), without unequivocal imaging-detected and/or clinical extranodal extension
N2	Tumor involvement of > 3 lymph nodes OR Tumor involvement of any lymph node(s), with unequivocal imaging-detected and/or clinical extranodal extension

Definition of Regional Lymph Nodes (N) Pathological N (pN)

N Category	N Criteria
NX	Regional lymph nodes cannot be assessed
N0	No tumor involvement of regional lymph node(s)
N1	Tumor involvement of 1-3 lymph node(s), without definitive pathological extranodal extension
N2	Tumor involvement of > 3 lymph nodes OR Tumor involvement of any lymph node(s), with definitive pathological extranodal extension

Regional Lymph Nodes Suffix

(sn) Sentinel node procedure

(f) FNA or core needle biopsy

Definition of Distant Metastasis (M)

M Category	M Criteria
cM0	No distant metastasis
cM1	Distant metastasis
pM1	Microscopic confirmation of distant metastasis

AJCC Prognostic Stage Groups

When T is...	And N is...	And M is...	Then the stage group is...
Tis	N0	M0	0
T1	N0	M0	I
T2	N0	M0	II
T1-T2	N1	M0	IIIA
T3-T4	N0	M0	IIIA
T1-T2	N2	M0	IIIB
T3-T4	N1-N2	M0	IIIB
Any T	Any N	M1	IV

AJCC Stage Group			
	N0	N1	N2
Tis	0	-	-
T1	I	IIIA	IIIB
T2	II	IIIA	IIIB
T3	IIIA	IIIB	IIIB
T4	IIIA	IIIB	IIIB
M1	IV	IV	IV

References :

<https://www.facs.org/quality-programs/cancer-programs/american-joint-committee-on-cancer/version-9/>

https://www.amazon.com/gp/product/B0G2TCQOBM?ref_=dbs_m_mng_rwt_calw_tkin_16&storeType=ebooks&qid=1763560154&sr=8-13

Oropharynx (HPV-Associated)

Summary of Changes :

- Changed from HPV-Mediated (p16+) Oropharyngeal Cancer to Oropharynx (HPV-Associated)
- Pharyngeal tonsil (adenoid) and tubal tonsils have been moved to the nasopharynx staging system
- Anterior surface of epiglottis has been included in this staging system and removed from the larynx staging system
- Addition of unequivocal imaging-detected extranodal extension (iENE) and/or clinical extranodal extension as a cN criterion: **iENE or clinical ENE increases N1 and N2 by one category**
- Addition of definitive pathologic extranodal extension (pENE) as a pN criterion: **pENE increases N1 and N2 by one category**
- Pathological N1 without definitive pENE is subdivided into **N1a (single node without definitive pENE) and N1b (2-4 nodes without definitive pENE)**
- Pathological stage II is revised to include T0-T2 N2-N3 M0 or T3 N0-N2 M0
- Pathological stage III is revised to include T3 N3 M0 or T4 Any N M0

Definition of primary Tumor (T) (紅字增修處)

T Category	T Criteria
T0	No evidence of primary tumor identified
T1	Tumor ≤ 2 cm or smaller in greatest dimension
T2	Tumor > larger than 2 cm but not larger than ≤ 4 cm in greatest dimension
T3	Tumor > larger than 4 cm in greatest dimension or extension to lingual surface of epiglottis
T4	<p>Tumor invades any of the following :</p> <ul style="list-style-type: none"> • Larynx* • Deep/extrinsic muscle of the tongue (genioglossus, hyoglossus, palatoglossus, and styloglossus) • Pterygoid muscles (medial and/or lateral) • Hard palate • Mandible • Pterygoid plates (medial and/or lateral) • Nasopharynx • Skull base • Encases carotid artery <p>Moderately advanced local disease</p> <p>Tumor invades the larynx, extrinsic muscle of tongue, medial pterygoid, hard palate, or mandible or beyond*</p>

*Mucosal extension to lingual surface of epiglottis from primary tumors of the base of the tongue and vallecula does not constitute invasion of the larynx.

Definition of Regional Lymph Node (N) Clinical N (cN) (紅字增修處)

N Category	N Criteria
NX	Regional lymph nodes cannot be assessed
N0	No tumor involvement of regional lymph node(s) metastasis
N1	Tumor involvement of ipsilateral lymph node(s), all ≤ 6 cm in greatest dimension, without unequivocal imaging-detected and/or clinical extranodal extension One or more ipsilateral lymph nodes, none larger than 6 cm
N2	Tumor involvement of ipsilateral lymph node(s), all ≤ 6 cm in greatest dimension, with unequivocal imaging-detected and/or clinical extranodal extension OR Tumor involvement of contralateral or bilateral lymph node(s), all ≤ 6 cm in greatest dimension without unequivocal imaging-detected and/or clinical extranodal extension Contralateral or bilateral lymph nodes, none larger than 6 cm
N3	Tumor involvement of lymph node(s) > 6 cm in greatest dimension OR Tumor involvement of contralateral or bilateral lymph node(s) with unequivocal imaging-detected and/or clinical extranodal extension Lymph node(s) larger than 6 cm

Definition of Regional Lymph Node (N) Pathological N (pN) (紅字增修處)

N Category	N Criteria
NX	Regional lymph nodes cannot be assessed
pN0	No tumor involvement of regional lymph node(s) metastasis
pN1	Tumor involvement of 1-4 lymph nodes without definitive pathological extranodal extension Metastasis in 4 or fewer lymph nodes
N1a	Tumor involvement of 1 lymph node without definitive pathological extranodal extension
N1b	Tumor involvement of 2-4 lymph nodes without definitive pathological extranodal extension
pN2	Tumor involvement of 1-4 lymph nodes with definitive pathological extranodal extension OR Tumor involvement of > 4 lymph nodes without definitive pathological extranodal extension Metastasis in more than 4 lymph nodes
N3	Tumor involvement of > 4 lymph nodes with definitive pathological extranodal extension

Definition of Distant Metastasis (M) (紅字增修處)

M Category	M Criteria
cM0	No distant metastasis
cM1	Distant metastasis
pM1	Microscopic confirmation of distant metastasis

AJCC Prognostic Stage Groups (紅字增修處)

Clinical Stage Group Table

When T is...	And N is...	And M is...	Then the stage group is...
T0	N1	M0	I
T0 , T1-T2	N0-N1	M0	I
T0-T2	N2	M0	II
T3	N0-N2	M0	II
T0-T3 T4	N3	M0	III
T4	Any N N0, N1, N2 or N3	M0	III
Any T	Any N	M1	IV

Pathological Stage Group Table

When T is...	And N is...	And M is...	Then the stage group is...
T0	N1	M0	I
T0 , T1-T2	N0-N1	M0	I
T0-T2	N2-N3	M0	II
T3 or T4	N0-N2 N1	M0	II
T3 or T4	N3 N2	M0	III
T4	Any N	M0	III
Any T	Any N	M1	IV

References :

<https://www.facs.org/quality-programs/cancer-programs/american-joint-committee-on-cancer/version-9/>

https://www.amazon.com/gp/product/B0G2TCQQB?ref_=db_s_m_mng_rwt_calw_tkin_16&storeType=ebooks&qid=1763560154&sr=8-13

Salivary Glands

Summary of Changes :

- Changed from Major Salivary Glands to Salivary Glands as the staging system now includes minor salivary glands
- Includes **major and minor salivary glands**
- Removal of squamous cell carcinoma (SCC), neuroendocrine, basosquamous cell since they are not typical salivary gland origin
- Almost all SCCs in salivary gland are metastatic nodes from a skin primary or rarely from a mucosal primary
- Consolidation of major and minor salivary gland T category definitions
Clarification of the definition of:
 - Extraparenchymal extension for T3
 - Bone invasion for T4
- Replacement of laterality with clinical lymph node number (1-3 vs > 3)
- Elimination of the cN3 category
- Addition of imaging-detected extranodal extension (iENE) in addition to clinical ENE as a cN criteria:
 - N1: 1-3 lymph nodes involved, **without** unequivocal iENE and/or clinical ENE
 - N2: > 3 lymph nodes involved, or any lymph node **with** unequivocal iENE and/or clinical ENE
- Replacement of laterality with pathological lymph node number (1-3 vs > 3)
- Elimination of the pN3 category
- Simplification of pN-positive categories:
 - N1: 1-3 lymph nodes involved **without** definitive pENE
 - N2: > 3 lymph nodes involved, or any lymph node **with** definitive pENE
- Confinement of M0 disease in Stages I, II, IIIA and IIIB, while reserving stage IV for M1 disease
 - Stage I: T1 N0
 - Stage II: T2 N0
 - Stage IIIA: T1-T2 N1 or T3-T4 N0
 - Stage IIIB: T1-T2 N2 or T3-T4 N1-N2

Definition of primary Tumor (T) (紅字增修處)

T Category	T Criteria
TX	Primary tumor cannot be assessed
T0	No evidence of primary tumor
Tis	Carcinoma <i>in situ</i>
T1	Tumor \leq 2 cm or smaller in greatest dimension without extraparenchymal extension*
T2	Tumor $>$ larger than 2 cm but \leq not larger than 4 cm in greatest dimension without extraparenchymal extension*
T3	<ul style="list-style-type: none"> Tumor $>$ larger than 4 cm in greatest dimension and/or tumor having extraparenchymal extension* Gross extraparenchymal extension (for major salivary glands)*
T4	Tumor invades immediately and/or beyond adjacent structures Moderately advanced or very advanced disease
T4a	<p>Tumor invades any immediately adjacent structures including:</p> <ul style="list-style-type: none"> Skin Bone** Cartilage Solid organ parenchyma Esophagus Trachea Named nerve <p>Moderately advanced disease Tumor invades skin, mandible, ear canal, and/or facial nerve</p>
T4b	<p>Tumor invades beyond any adjacent structures including:</p> <ul style="list-style-type: none"> Encasement of carotid artery Base of skull invasion (except nasopharynx) Spinal column invasion Intracranial invasion Orbital apex Prevertebral space Mediastinal structures Masticator space <p>Very advanced disease Tumor invades skull base and/or pterygoid plates and/or encases carotid artery</p>

*Extraparenchymal extension is clinical or macroscopic evidence of invasion of soft tissues or **nerve, except those listed under T4a and T4b**. Microscopic evidence alone does not constitute extraparenchymal extension for classification purposes.

**The following scenarios are not considered T category defining "bone invasion":

1) Destruction of intrinsic sinus bone in sinonasal primaries; 2) Erosion of cortical bone; 3) Primary intraosseous (central) salivary gland tumors.

Definition of Regional Lymph Node (N) Clinical N (cN) (紅字增修處)

N Category	N Criteria
NX	Regional lymph nodes cannot be assessed
N0	No tumor involvement of regional lymph node(s) metastasis
N1	Tumor involvement of 1-3 lymph node(s), without unequivocal imaging-detected and/or clinical extranodal extension Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(-)
N2	Tumor involvement of > 3 lymph nodes OR Tumor involvement of any lymph node(s), with unequivocal imaging-detected and/or clinical extranodal extension Metastasis in a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-) ; or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-) ; or in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-)
N2a	Metastasis in a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-)
N2b	Metastases in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension and ENE(-)
N2e	Metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-)
N3	Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-) ; or metastasis in any node(s) with clinically overt ENE(+)
N3a	Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-)
N3b	Metastasis in any node(s) with clinically overt ENE(+)

Definition of Regional Lymph Node (N) Pathological N (pN) (紅字增修處)

N Category	N Criteria
NX	Regional lymph nodes cannot be assessed
N0	No tumor involvement of regional lymph node(s) metastasis
N1	Tumor involvement of 1-3 lymph node(s), without definitive pathological extranodal extension Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(-)
N2	Tumor involvement of > 3 lymph nodes OR Tumor involvement of any lymph node(s), with definitive pathological extranodal extension Metastasis in a single ipsilateral lymph node, 3 cm or smaller in greatest dimension and ENE(+); or larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-); or metastases in multiple ipsilateral lymph nodes, none larger than 6 cm in greatest dimension and ENE(-); or in bilateral or contralateral lymph node(s), none larger than 6 cm in greatest dimension and ENE(-)
N2a	Metastasis in single ipsilateral node 3 cm or smaller in greatest dimension and ENE(+); or a single ipsilateral node larger than 3 cm but not larger than 6 cm in greatest dimension and ENE(-)
N2b	Metastases in multiple ipsilateral nodes, none larger than 6 cm in greatest dimension, and ENE(-)
N2e	Metastases in bilateral or contralateral lymph nodes, none larger than 6 cm in greatest dimension, and ENE(-)
N3	Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-); or metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral nodes, any with ENE(+); or a single contralateral node of any size and ENE(+)
N3a	Metastasis in a lymph node larger than 6 cm in greatest dimension and ENE(-)
N3b	Metastasis in a single ipsilateral node larger than 3 cm in greatest dimension and ENE(+); or multiple ipsilateral, contralateral, or bilateral nodes any with ENE(+); or a single contralateral node of any size and ENE(+)

Definition of Distant Metastasis (M) (紅字增修處)

M Category	M Criteria
cM0	No distant metastasis
cM1	Distant metastasis
pM1	Microscopic confirmation of distant metastasis

AJCC Prognostic Stage Groups (紅字增修處)

When T is...	And N is...	And M is...	Then the stage group is...
Tis	N0	M0	0
T1	N0	M0	I
T2	N0	M0	II
T0 T1-T2 T3	N1	M0	III A
T3-T4	N0	M0	III A
T4a	N0, N1	M0	IV A
T0 T1-T2 T3 T4a	N2	M0	IV A III B
T3-T4	N1-N2	M0	III B
Any T	N3	M0	IV B
T4b	Any N	M0	IV B
Any T	Any N	M1	IV C

References :

<https://www.facs.org/quality-programs/cancer-programs/american-joint-committee-on-cancer/version-9/>

https://www.amazon.com/gp/product/B0G2TCQQBM?ref_=dbs_m_mng_rwt_calw_tkin_16&storeType=ebooks&qid=1763560154&sr=8-13